Join our daily newsletter At The Bell to receive exclusive market insights
- Respiri (RSH) begins onboarding patients in the short wheezo remote patient monitoring (RPM) pilot program
- Respiri, and partner Access Telehealth, will provide a full solution including the Remotli platform, patient engagement and remote monitoring under the supervision of the Minnesota Lung Centre (MLC)
- The pilot program will run for two months, after which it will be integrated into MLC systems and rolled-out as part of standard of care to respiratory patients
- Moving forward, Respiri and Access Telehealth are in discussions with several other potential wheezo RPM customers
- Respiri is up 2.5 per cent, trading at 4.1 cents at 12:30 pm AEDT
Respiri (RSH) has begun onboarding patients in the short wheezo remote patient monitoring (RPM) pilot program.
The wheezo device analyses breath sounds for wheeze, allowing patients to log symptoms and triggers to build a profile which can be shared with healthcare providers.
Respiri, in collaboration with its RPM partner Access Telehealth, will provide a full solution that includes the Remotli platform, patient engagement and remote monitoring to patients under the supervision of the Minnesota Lung Centre (MLC).
The pilot program has been reduced from three months to two, after which the wheezo RPM program will be integrated into MLC systems and rolled-out as part of standard of care to respiratory patients with both asthma or chronic obstructive pulmonary disease (COPD).
The company said reimbursement codes from this program will be processed through Medicaid Services and private insurers to ensure MLC is remunerated for providing the patient service.
In addition to the device sale, Respiri will receive recurring RPM revenues per patient, per month for reimbursed services claimed by MLC.
Respiri CEO Marjan Mikel said the wheezo RPM program has the potential to make “material differences” to the lives of many respiratory patients.
“The relationship we have developed with Minnesota Lung Centre and Access Telehealth allows Respiri to deliver a unique world class solution and future commercial rewards,” Mr Mikel said.
Respiri and Access Telehealth are in discussions with several other potential wheezo RPM customers.
Respiri was up 2.5 per cent, trading at 4.1 cents at 12:30 pm AEDT.
